Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,712,000
+2,000 (0.12%)
Feb 11, 2026, 3:30 PM KST

Samsung Biologics Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,456,000391,222367,937890,82047,410
Short-Term Investments
-940,0671,688,3382,204,212473,985
Trading Asset Securities
---98,506850,040
Cash & Short-Term Investments
1,456,0001,331,2892,056,2763,193,5371,371,435
Cash Growth
9.37%-35.26%-35.61%132.86%60.96%
Accounts Receivable
----0
Receivables
----0
Inventory
-2,818,2762,641,3682,375,8191,012,871
Prepaid Expenses
-28,25126,83023,2018,579
Other Current Assets
2,952,0001,340,302797,513865,099430,291
Total Current Assets
4,408,0005,518,1185,521,9886,457,6572,823,175
Property, Plant & Equipment
-5,837,4824,342,4243,871,4522,227,687
Long-Term Investments
-59,60547,43538,1102,661,499
Goodwill
-1,677,6081,677,6081,677,608-
Other Intangible Assets
-1,294,7051,580,4231,541,85032,172
Long-Term Accounts Receivable
-00-00
Long-Term Deferred Tax Assets
-165.09---
Long-Term Deferred Charges
-2,592,9902,574,0572,741,848-
Other Long-Term Assets
6,653,000355,592302,236253,524225,477
Total Assets
11,061,00017,336,29616,046,19716,582,0507,970,011
Accounts Payable
-177,992201,70959,61632,251
Accrued Expenses
-545,403281,317207,43774,322
Short-Term Debt
-207,000654,500582,78350,000
Current Portion of Long-Term Debt
-120,000733,405556,017109,855
Current Portion of Leases
-138,594144,031142,2477,537
Current Income Taxes Payable
-375,388191,212223,299110,174
Current Unearned Revenue
-400,007399,818432,680-
Other Current Liabilities
2,533,0001,888,8041,551,8701,977,462723,156
Total Current Liabilities
2,533,0003,853,1884,157,8614,181,5421,107,295
Long-Term Debt
919,0001,012,757239,783965,0901,114,684
Long-Term Leases
-7,889137,614267,89610,671
Pension & Post-Retirement Benefits
-5,5475,117--
Long-Term Deferred Tax Liabilities
-972,0621,184,4201,214,216487,712
Other Long-Term Liabilities
158,000580,177490,910968,833258,547
Total Liabilities
3,610,0006,431,6206,215,7057,597,5762,978,909
Common Stock
116,000177,935177,935177,935165,413
Additional Paid-In Capital
3,392,0005,663,1115,663,1115,663,1112,487,313
Retained Earnings
6,871,0005,086,6094,003,2933,145,6012,347,187
Comprehensive Income & Other
-2,928,000-22,979-13,847-2,173-8,811
Shareholders' Equity
7,451,00010,904,6769,830,4928,984,4744,991,102
Total Liabilities & Equity
11,061,00017,336,29616,046,19716,582,0507,970,011
Total Debt
919,0001,486,2391,909,3332,514,0331,292,747
Net Cash (Debt)
537,000-154,951146,943679,50478,688
Net Cash Growth
---78.38%763.54%17.19%
Net Cash Per Share
11600.54-3347.323174.3414965.871828.54
Filing Date Shares Outstanding
46.2946.2946.2946.2943.03
Total Common Shares Outstanding
-46.2946.2946.2943.03
Working Capital
1,875,0001,664,9291,364,1272,276,1151,715,881
Book Value Per Share
160960.19235568.21212363.16194087.06115982.76
Tangible Book Value
7,451,0007,932,3636,572,4615,765,0164,958,931
Tangible Book Value Per Share
160960.19171358.83141981.56124538.73115235.15
Land
-141,114141,065141,065-
Buildings
-1,956,9581,943,6941,376,222832,519
Machinery
-2,629,5982,525,3441,811,9821,380,919
Construction In Progress
-1,833,097202,411825,199583,360
Source: S&P Global Market Intelligence. Standard template. Financial Sources.